Arrowhead Pharmaceuticals Inc.

In News

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) - Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. - Jun 22, 2026

Is Arrowhead Pharmaceuticals on the Cusp of a Major Breakout - Kavout | AI

Kavout | AI - Jun 24, 2026

Arrowhead Pharmaceuticals (ARWR) Leads Healthcare Stocks with St - GuruFocus

GuruFocus - Jun 24, 2026

Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars - Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. - Jun 18, 2026

Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech’s Solid Start to 2026 - Yahoo Finance

Yahoo Finance - May 26, 2026

Arrowhead Pharmaceuticals (ARWR) Receives EU Approval for REDEMP - GuruFocus

GuruFocus - Jun 22, 2026

Arrowhead Pharmaceuticals Inc. (ARWR): Billionaire Ken Fisher Bets Big on Pharma - Yahoo Finance

Yahoo Finance - Mar 17, 2026

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results - Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. - Apr 20, 2026

Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events - Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. - Feb 24, 2026

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results - Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. - Jan 20, 2026

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) - Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. - Nov 18, 2025

Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events - Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. - Dec 23, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment